Core Viewpoint - The analysis compares BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY) to determine which stock is more attractive to value investors [1]. Group 1: Zacks Rank and Earnings Outlook - BMRN has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while CSLLY has a Zacks Rank of 5 (Strong Sell) [3]. - The Zacks Rank system emphasizes companies with positive earnings estimate revisions, suggesting that BMRN's earnings outlook is improving more significantly than CSLLY's [3][7]. Group 2: Valuation Metrics - BMRN has a forward P/E ratio of 15.85, compared to CSLLY's forward P/E of 22.76, indicating that BMRN may be undervalued relative to CSLLY [5]. - The PEG ratio for BMRN is 0.44, while CSLLY's PEG ratio is 1.47, further suggesting that BMRN is a more attractive value option [5]. - BMRN's P/B ratio is 2.24, significantly lower than CSLLY's P/B of 4.03, reinforcing the notion that BMRN is undervalued [6]. - These metrics contribute to BMRN's Value grade of B and CSLLY's Value grade of F, highlighting BMRN's superior valuation [6].

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth S ...

SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update.Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 1878833U.S. / Canada ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estim ...

This is my third BioMarin (NASDAQ: BMRN ) article following 07/2024's "BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal" (" Big Reveal "). In the interim BioMarin has dropped >26%. Whenever a company loses that much that fast a fundamental question arises; is itWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share m ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the trad ...

The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity is likely to accelerate in 2025 with a change in administration and expected d ...

Legal Action and Patent Infringement - BioMarin Pharmaceutical Inc has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany [1] - The patent covers long-acting variants of C-Type Natriuretic Peptide (CNP) [1] - The legal action is based on BioMarin's belief that Ascendis' TransCon CNP investigational product and its development program in Germany and elsewhere in Europe infringe BioMarin's patent [2] - The BioMarin patent was confirmed by the European Patent Office's Opposition Division in 2024 [2] Unified Patent Court (UPC) Jurisdiction - The UPC, which formally started in June 2023, has jurisdiction over European patents for 18 European member states that have ratified the Unitary Patents (UPs) [3] - These member states include Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Romania, Slovenia, and Sweden [3] Company Background and Commitment - BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient [4] - The company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline [4] - BioMarin is committed to protecting the important inventions its scientists make for patients around the world, including the more than 15 years of scientific research that supported VOXZOGO® and BMN 333, its long-acting CNP [4] Trademarks and Contacts - BioMarin® and VOXZOGO® are registered trademarks of BioMarin Pharmaceutical Inc [6] - Contacts for investors and media are Traci McCarty and Andrew Villani, respectively [7]

Stock Performance and Price Targets - BioMarin Pharmaceutical (BMRN) shares have gained 2.1% over the past four weeks, closing at $67.38 [1] - The mean price target estimate of $98.28 indicates a potential upside of 45.9% [1] - The average price target comprises 25 estimates ranging from $65 to $138, with a standard deviation of $17.42 [2] - The lowest estimate suggests a 3.5% decline, while the most optimistic estimate points to a 104.8% upside [2] Analyst Consensus and Earnings Estimates - Strong agreement among analysts about the company's ability to report better earnings strengthens the view of a potential upside [4] - The Zacks Consensus Estimate for the current year has increased 4.3% over the past month, with one positive revision and no negative revisions [10] - BMRN currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks [11] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets to generate interest in companies with which their firms have business relationships [6] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts [7] - Empirical research shows that price targets rarely indicate where a stock's price is actually heading [5] Investment Considerations - While price targets should not be entirely ignored, making investment decisions solely based on them could lead to disappointing returns [8] - The direction of price movement implied by the consensus price target appears to be a good guide, even if the target itself is not reliable [12]

SAN RAFAEL, Calif., Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P. Morgan Conference on Monday, January 13, 2024, at 9:00 am PT / 12:00 pm ET, in San Francisco, California. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available thro ...